Biometric CRO Quanticate will work with PhaseV, a machine learning company developing software for clinical trials, to launch a new service that aims to help sponsors design and optimize adaptive ...

Chapel Hill-based University of North Carolina Lineberger Comprehensive Cancer Center has been awarded up to $28 million to develop an adaptive clinical trial targeting metastatic breast cancer. The ...

BOSTON, Oct. 24, 2023 /PRNewswire/ -- PhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 million in ...

The press release below was prepared by the Pancreatic Cancer Action Network. View the original here. The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic ...

Gastrointestinal-focused CRO Alimentiv is upgrading its clinical trials with software firm PhaseV’s adaptive trial technology. In a new collaboration, Alimentiv will combine PhaseV's machine learning ...

The first-ever adaptive clinical trial for Australians living with MS will seek to reverse neurological damage caused by progressive multiple sclerosis. With an initial $4 million in funding, the ...

AUSTIN, Texas--(BUSINESS WIRE)--Berry Consultants, LLC announced today that FACTS 7 was released to existing users and is now available to all new clients. FACTS (Fixed and Adaptive Clinical Trial ...

SEATTLE, Dec. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

Adaptive clinical trials use algorithms to predict, during the study, patient outcomes and final study results. These predictions trigger interim decisions, such as early discontinuation of the trial, ...

clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial ...

Post hoc analysis of the AdaptResponse global randomized trial suggests the value of adaptive vs conventional cardiac resynchronization therapy (CRT) in patients with symptomatic heart failure (HF), ...